Elicio Therapeutics (ELTX) Total Current Liabilities (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Total Current Liabilities for 7 consecutive years, with $9.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 7.27% year-over-year to $9.2 million; the trailing twelve-month figure through Jun 2026 stood at $9.2 million (down 7.27% YoY), and the FY2025 full-year result was $8.1 million, down 29.62% from the prior year.
• Total Current Liabilities grew to $9.2 million in Q2 2026 per ELTX's latest filing, from $7.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $11.5 million in Q4 2024 and bottomed at $2.0 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $8.4 million across 5 years, with a median of $8.1 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities tumbled 80.44% in 2023, then surged 193.01% in 2024.
• Over 5 years, Total Current Liabilities stood at $6.9 million in 2022, then jumped by 42.04% to $9.8 million in 2023, then climbed by 18.12% to $11.5 million in 2024, then decreased by 29.62% to $8.1 million in 2025, then increased by 13.46% to $9.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $9.2 million, $7.2 million, and $8.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.